What the Midterm Elections Mean for Healthcare

Policy Update Midterm Elections 1200x628px 1

From Medicaid and health insurance coverage to prescription drug pricing and federal healthcare funding, the results of Tuesday's midterm elections could have far-reaching implications for healthcare providers and the patients they serve. With Democrats poised to take control of both chambers of Congress in January, healthcare affordability and expanded congressional oversight are expected to take center stage in Washington.

First, a Consequential Lame-Duck Session

Before the new Congress convenes, lawmakers face a compressed legislative calendar and several important deadlines.

The current Republican-controlled Congress is scheduled to return Nov. 9 for its final weeks, with government funding and annual defense legislation expected to dominate the agenda. Federal stopgap funding expires Dec. 11, creating pressure to negotiate a spending agreement or another temporary extension to avoid a government shutdown.

Healthcare organizations will also be watching a Dec. 31 deadline for approximately 20 expiring healthcare provisions, including funding for community health centers and temporary Medicare physician payment adjustments.

The election results could complicate negotiations. Some lawmakers favor resolving outstanding spending and policy matters before year-end, while others may prefer to defer decisions until Democrats assume control and have greater negotiating leverage.

For healthcare providers, the immediate concern is whether Congress can reach agreements that preserve funding stability and prevent disruptions to essential programs.

A New Congress, a New Healthcare Agenda

When the 120th Congress convenes Jan. 3, Democrats will control the legislative agenda, committee leadership and congressional oversight in both chambers.

Democratic leadership has identified healthcare affordability and coverage as early priorities, particularly efforts to reverse Medicaid reductions enacted under the 2025 One Big Beautiful Bill Act and restore enhanced Affordable Care Act (ACA) premium tax credits that expired at the end of 2025.

These issues have significant implications for healthcare organizations. Changes in Medicaid eligibility and financing, along with the affordability of marketplace insurance coverage, can influence patient access, uncompensated care and the financial stability of providers serving vulnerable populations.

Beyond Medicaid and ACA coverage, lawmakers are expected to revisit prescription drug pricing, Medicare drug price negotiations, healthcare price transparency and potential reforms to the 340B Drug Pricing Program. Other areas where bipartisan agreement may be possible include Medicare physician payment reform, efforts to reduce prior authorization delays and changes to the dispute resolution process under the No Surprises Act.

Democrats may also advance more ambitious proposals to expand coverage and reduce costs, potentially laying the groundwork for healthcare policy debates ahead of the 2028 presidential election.

However, Democratic control of Congress does not guarantee legislative success. Most legislation will still require 60 votes to advance in the Senate, and President Trump retains veto authority. While ACA subsidies and prescription drug pricing could provide opportunities for negotiation, efforts to reverse Medicaid reductions may face greater resistance.

Congressional Oversight Takes Center Stage

One of the most immediate consequences of the election may be a substantial expansion of congressional oversight of federal healthcare agencies and administration policies.

Democrats will assume leadership of influential committees, including Senate Finance, Senate Health, Education, Labor and Pensions (HELP), House Energy and Commerce, and House Ways and Means. Changes in health subcommittee leadership will further reshape the congressional healthcare agenda.

These committees are expected to scrutinize implementation of the 2025 tax law, federal healthcare spending, regulatory decisions and agreements between the administration and healthcare industry stakeholders. Oversight may also extend to health insurers, pharmaceutical companies and healthcare consolidation.

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and the administration's Make America Healthy Again initiative may face particular attention, especially regarding vaccine policy, public health guidance and federal health agency operations. Some issues associated with the movement, including nutrition, food safety and chronic disease prevention, could also provide opportunities for bipartisan discussion.

With Democrats controlling the Senate, the administration may encounter significant resistance to confirming new HHS nominees, potentially leaving senior agency vacancies unfilled.

What Healthcare Leaders Should Watch

The new Congress will face consequential decisions almost immediately. The president's fiscal year 2028 budget request is due Feb. 1, and the federal debt limit could be reached as soon as February, creating additional pressure for negotiations over spending priorities.

Looking further ahead, prescription drug and medical device user fee authorizations expire Sept. 30, 2027, creating another important legislative deadline and potential opportunity for broader healthcare policy negotiations.

While the direction of federal healthcare policy remains uncertain, the election has established a new balance of power that will influence healthcare priorities, funding decisions and regulatory activity over the next two years. For providers navigating financial pressures, workforce challenges and evolving patient needs, understanding these developments will be essential to planning for the year ahead.

Back to all News